Patent: 9,469,689
✉ Email this page to a colleague
Summary for Patent: 9,469,689
| Title: | Therapeutic DLL4 binding proteins |
| Abstract: | DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. |
| Inventor(s): | Chen; Ming-Jiu (Shrewsbury, MA), Hsieh; Chung-Ming (Newton, MA), Gu; Jijie (Shrewsbury, MA), Morgan-Lappe; Susan E. (Riverwoods, IL), Li; Yingchun (Buffalo Grove, IL) |
| Assignee: | AbbVie Inc. (North Chicago, IL) |
| Application Number: | 14/798,849 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,469,689
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | 11/18/2011 | ⤷ Try a Trial | 2030-03-02 |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | 08/16/2018 | ⤷ Try a Trial | 2030-03-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
